PMID- 11468644
OWN - NLM
STAT- MEDLINE
DCOM- 20010913
LR  - 20161124
IS  - 0828-282X (Print)
IS  - 0828-282X (Linking)
VI  - 17
IP  - 7
DP  - 2001 Jul
TI  - Tumour necrosis factor-alpha soluble receptors type I are related to symptoms and 
      left ventricular function in hypertrophic cardiomyopathy.
PG  - 777-84
AB  - BACKGROUND: High circulating levels of tumour necrosis factor-alpha (TNF-alpha) 
      and its soluble receptors (sTNFRI, sTNFRII) are involved in the pathogenesis of 
      congestive heart failure due to left ventricular (LV) systolic dysfunction. 
      However, their role in hypertrophic cardiomyopathy (HCM) has not been elucidated. 
      OBJECTIVES: To determine the circulating serum levels of sTNFRI in a wide 
      spectrum of patients with HCM, and to study in detail their relationship with 
      symptom severity and various echocardiographic disease characteristics. PATIENTS 
      AND METHODS: sTNFRI serum levels were measured in 66 patients with HCM and 30 
      age-matched healthy subjects using enzyme linked immunosorbent assay for serum 
      levels of soluble TNF-a receptor type I at rest and at 1, 3 (sTNFRI-3e) and 6 h 
      after dobutamine stress echocardiography (DSE). RESULTS: sTNFRI-r levels were 
      significantly higher in patients with HCM than in control subjects (2.8+/-0.8 
      compared with 1.4+/-0.5 ng/mL, P<0.002). In patients with HCM, there was a 
      significant difference in sTNFRI-r levels between mildly (New York Heart 
      Association [NYHA] functional class I and II) and severely (NYHA functional class 
      III and IV) symptomatic patients (1.4+/-0.9 compared with 4.8+/-1.0 ng/mL, 
      p<0.001). Higher sTNFRI-r and sTNFRI-3e levels were found in patients with an LV 
      restrictive filling pattern during DSE compared with sustained abnormal 
      relaxation (p<0.052, p<0.004, respectively), and in patients with reduced 
      compared with normal increments in LV fractional shortening during DSE (p<0.02, 
      p<0.003, respectively). CONCLUSIONS: Significant differences in sTNFRI serum 
      levels between patients with HCM and healthy subjects were shown. In patients 
      with HCM, sTNFRI levels were higher in severely symptomatic patients, and in 
      patients with reduced LV systolic and diastolic reserve during DSE. These data 
      suggest that TNF may be involved in the pathogenesis of HCM.
FAU - Penicka, M
AU  - Penicka M
AD  - Cardiocentre, Charles University, Prague, Czech Republic. 
      martinpenicka@hotmail.com
FAU - Gregor, P
AU  - Gregor P
FAU - Krupicka, J
AU  - Krupicka J
FAU - Jira, M
AU  - Jira M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 3S12J47372 (Dobutamine)
SB  - IM
MH  - Adult
MH  - Cardiomyopathy, Hypertrophic/*blood/diagnostic imaging/*etiology
MH  - Case-Control Studies
MH  - Dobutamine
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*blood
MH  - Ventricular Function, Left/*physiology
EDAT- 2001/07/27 10:00
MHDA- 2001/09/14 10:01
CRDT- 2001/07/27 10:00
PHST- 2001/07/27 10:00 [pubmed]
PHST- 2001/09/14 10:01 [medline]
PHST- 2001/07/27 10:00 [entrez]
PST - ppublish
SO  - Can J Cardiol. 2001 Jul;17(7):777-84.